Trial Profile
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pepinemab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Vaccinex
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 20 Oct 2015 Results were published in a Vaccinex media release.
- 07 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research